tbuckley/cabot-search huggingface dataset:
Secretion of Angiogenic Proteins by Human Multipotent Mesenchymal Stromal Cells (MSC) under Hypoxic Culture Conditions and Clinical Application of MSC in Steroid Induced Osteonecrosis in Children.
Authors: Ingo Müller, Martin Vaegler, Christina Holzwarth, Burkhardt Schütt, Stefan M. Pfister, Johann Greil, Maximilian Rudert, Rupert Handgretinger
Journal: Blood (2007)
Regulation of humoral immunity by gut microbial products
Authors: Myunghoo Kim, Chang H. Kim
Journal: Gut Microbes (2017)

The intestinal tract provides ideal niches for several different microbial species, which are collectively called the gut microbiota. A key host immune effector that controls the microbiota and prevents mucosal infection is IgA. Gut microbiota-derived factors are largely classified into molecular pattern recognition receptor ligands and nutrient-derived metabolites including short-chain fatty acids and adenosine triphosphate. Along with host-derived factors such as retinoic acid, various cytokines and cytokine-like molecules, gut microbial products profoundly shape B cell responses. Gut microbial products can directly regulate B cell activation and differentiation. They can also indirectly affect B cells through epithelial cells, T cells, and myeloid cell subsets. We highlight the various direct and indirect mechanisms by which microbial products regulate humoral immunity.
Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice
Authors: Giada De Palma, Michael D. J. Lynch, Jun Lu, Vi T. Dang, Yikang Deng, Jennifer Jury, Genevieve Umeh, Pedro M. Miranda, Marc Pigrau Pastor, Sacha Sidani, Maria Ines Pinto-Sanchez, Vivek Philip, Peter G. McLean, Moreno-Gabriel Hagelsieb, Michael G. Surette, Gabriela E. Bergonzelli, Elena F. Verdu, Philip Britz-McKibbin, Josh D. Neufeld, Stephen M. Collins, Premysl Bercik
Journal: Science Translational Medicine (2017)

Fecal microbiota transplants from patients with irritable bowel syndrome and anxiety alter gut function and behavior in germ-free mice.
The challenge of relational diagnoses: applying the biopsychosocial model in DSM-IV. Group for the Advancement of Psychiatry Committee on the Family
Journal: American Journal of Psychiatry (1989)

The meaningful application of the biopsychosocial model in psychiatry requires explicit attention to the relational or interpersonal level of functioning. Family-oriented researchers and clinicians recommend that, despite pressures for early publication of DSM-IV, the time has come to give a definitive place to relational syndromes in psychiatric nosology.
Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients.
Authors: Wendy B. London, Rochelle Bagatell, Brenda Weigel, Elizabeth Fox, Collin Van Ryn, Arlene Naranjo, Mark D. Krailo, Charlotte H. Ahern, Julie R. Park
Journal: Journal of Clinical Oncology (2014)

10034 Background: Early phase trials of investigational agents in pediatric patients (pts) with relapsed neuroblastoma (NB) historically used “response” per RECIST as the primary endpoint; response rate determined whether to test agents in Phase 3. Response assessment is challenging because NB in bone and bone marrow is not ‘measureable’. TTP and PFS endpoints are better suited to measure potential therapeutic benefit in NB, especially for targeted biologic agents and immunotherapies. Historical data on PFS or TTP exist only in small potentially biased NB cohorts. Herein, we study the largest cohort to date of relapsed/refractory NB pts, treated with modern era frontline and relapse therapy. We determined PFS, OS, & TTP, for use as historical comparators in future Phase 2 studies. Methods: 489 NB enrollments (consecutive 11/2002-1/2014), from 384 distinct pts, on 36 Phase 1 (27) or 2 (9) Children’s Oncology Group trials were analyzed for PFS (relapse, progression, death from disease), overall survival (OS) (death- any cause), & TTP, starting from Phase 1,2 trial enrollment. If pts were on multiple trials, enrollments were analyzed as if they were independent. For PFS, non-disease deaths were censored. Using RECIST, only 2 Phase 2 trials met the prospective response rate bar for success. For high-risk pts, planned frontline therapy included HSCT; 11.6% received ch14.18 antibody. Results: From relapse study enrollment: 1-year & 4-year PFS were 19±2% & 8±3%, respectively; 56±3% & 14±4% for OS; median TTP was 63 days (95% CI: 56,79). Median follow-up time in pts without progression was 9.7 mos. Risk factors at diagnosis were known in pt subsets: 88% of 230 - INSS stage 4; 92% of 230 - ≥18 mos old; 18% of 189 - MYCN amplified; 49% of 180 - diploid; 94% of 172 - unfavorable histology. Only MYCN amplification was prognostic of worse PFS after relapse study enrollment (p<0.001). Median time from diagnosis to first relapse/progression was 22 mos (95% CI: 19,25) (n=214). Conclusions: PFS/TTP/OS from this representative comprehensive historical COG early-phase trial NB cohort should be used in Phase 2 trials as the gold standard comparator to identify promising new agents for NB.
A comprehensive analysis of BRAF and KRAS mutation status in low-grade serous (LGS) and serous borderline (SB) ovarian cancer (OC).
Authors: Rachel Nicole Grisham, Karuna Garg, Qin Zhou, Alexia Iasonos, Michael F. Berger, Fanny Dao, David Michael Hyman, Douglas A. Levine, David B. Solit, Carol Aghajanian, Gopa Iyer
Journal: Journal of Clinical Oncology (2012)

5030 Background: LGS OC develops in a step-wise pattern from serous cystadenoma to SB tumor to invasive LGSOC. LGSOC accounts for 6-22% of serous OC and is a chemoresistant disease. Prior studies have reported that LGS/SB ovarian tumors harbor BRAF mutations in 28-35% of cases, suggesting that LGS/SB OC may respond to mutant BRAF inhibitors. Methods: We genotyped 75 LGS and SB ovarian tumors for BRAF and KRAS hotspot mutations using a mass spectrometry based Sequenom assay. All samples were collected at MSKCC between 2000-2010. All specimens underwent two independent pathologic reviews for diagnostic confirmation and macrodissection to ensure 80% cellularity. The incidence and identity of BRAF and KRAS mutations were defined and results were correlated with stage, response to treatment, and outcome. Exon capture sequencing is underway to sequence all coding exons of 230 cancer associated genes to identify additional targetable alterations in LGS/SB OC. Results: Of 75 samples examined, 56(75%) were SB and 19(25%) LGS histology. 57% of samples showed KRAS mutation (KRAS+) (n=17, 23%) or BRAF mutation (BRAF+) (n=26, 35%). Mutation status was mutually exclusive. All BRAF + were V600E, KRAS+ were G12D (n=9) or G12V (n=8). BRAF+ was associated with early stage (I-II) at presentation and SB histology. 22 (29%) patients were treated with chemotherapy, 2 (9%) with KRAS + and 0 with BRAF+. 4(15%) BRAF+ patients underwent resection of recurrent disease. All BRAF+ patients are alive without evidence of disease at a median follow-up of 43.3 months (range 1.9- 129.3 months). Conclusions: V600E BRAF mutations are present in 35% of cases of SB/LGS ovarian cancer. Presence of BRAF + in SB/LGS OC is associated with good prognosis and surgical cure of disease. Patients with SB/LGS OC who require systemic therapy are unlikely to have BRAF+. Our group is performing a detailed search for additional targetable alterations in multiple signal transduction pathways through next generation sequencing technology. [Table: see text]
Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer
Authors: Zhongling Wang, Ruirui Qiao, Na Tang, Ziwei Lu, Han Wang, Zaixian Zhang, Xiangdong Xue, Zhongyi Huang, Siruo Zhang, Guixiang Zhang, Yuanpei Li
Journal: Biomaterials (2017)
Killer Cell Immunoglobulin-Like Receptor (KIR) Ligands Predict Outcomes of Autologous Stem Cell Transplantation for AML
Authors: Heeje Kim, Tae-Hyang Lee, So-Hye Park, Hyun-Jeong Sohn, Hee-Baeg Choi, Yoo-Jin Kim, Tai-Gyu Kim, Woo-Sung Min
Journal: Blood (2010)
Foxp3 Expression Is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis
Authors: Xiao Ni, Lisa Shiue, Paola Arias-Mendoza, Erin Aakhus, Chitra Hosing, Madeleine Duvic
Journal: Blood (2008)
Severe Donor Events after Allogeneic Hematopoietic Stem Cell Donation.
Authors: Jörg Halter, Yoshihisa Kodera, Alvaro Urbano Ispizua, Hildegard Greinix, Norbert Schmitz, Geneviève Favre, Helen Baldomero, Diegter Niederwieser, Jane Apperley, Alois Gratwohl
Journal: Blood (2007)
Mobilization of Peripheral Blood Stem Cells with Rituximab Plus ESHAP Combination Regimen in B-Cell NHL - Preliminary Results.
Authors: Min Kyoung Kim, Shin Kim, Seong Sook Lee, Sun Jin Sym, Dae Ho Lee, Sang We Kim, Seongsoo Jang, Chan Jeong Park, Hyun Sook Chi, Joo Ryung Huh, Cheolwon Suh
Journal: Blood (2006)
Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma.
Authors: Michael A. Thompson, Barbara Pro, Andreas Sarris, Fredrick B. Hagemeister, Andre Goy, Archie Bleyer, Fernando F. Cabanillas, Felipe Samaniego, Luis E. Fayad
Journal: Blood (2005)
Clinical Implications of Clonal Cytogenetic Abnormalities of Aquired Aplastic Anemia.
Authors: Sung Hyun Kim, Ji Hyun Lee, Kyung A. Kwon, Suee Lee, Sung Yong Oh, Hyuk-Chan Kwon, Jin-Yeong Han, Moo-Kon Song, Joo-Seop Chung, Sang-Min Lee, Young-Don Joo, Ho Sup Lee, Yang Soo Kim, Hyo Jin Kim
Journal: Blood (2009)
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients
Authors: Devendra K. Hiwase, Deepak Singhal, Corinna Strupp, Rakchha Chhetri, Monika M. Kutyna, L. Amilia Wee, Peter B. Harrison, Shriram V. Nath, Nicholas Wickham, Chi‐Hung Hui, James X. Gray, Peter Bardy, David M. Ross, Ian D. Lewis, John Reynolds, L. Bik To, Ulrich Germing
Journal: American Journal of Hematology (2017)

RBC-transfusion dependency (RBC-TD) is an independent prognostic factor for poor overall survival (OS) in the WHO classification-based prognostic scoring system (WPSS) for MDS patients. However, WPSS did not include cytopenia, whereas revised International Prognostic Scoring System (IPSS-R) did not include RBC-TD. Thus, neither of these prognostic scoring systems incorporates both cytopenia and RBC-TD. We aimed to test whether RBC-TD adds prognostic value to the IPSS-R. We analyzed MDS patients not treated with disease-modifying therapy, and enrolled in SA-MDS Registry (derivation cohort; n = 295) and Dusseldorf registry (Germany; validation cohort; n = 113) using time-dependent Cox proportional regression and serial landmark analyses. In the derivation cohort, RBC-TD patients had inferior OS compared to RBC transfusion-independent (RBC-TI) patients (P < 0.0001) at 6- (18 vs. 64 months), 12- (24 vs. 71 months), and 24-months (40 vs. 87 months). In a Cox proportional regression analysis, RBC-TD was an independent adverse prognostic marker in addition to age, sex, and IPSS-R variables (P < 0.0001). A prognostic index (PI) was derived using these Cox-proportional regression model variables. In the validation cohort, this PI classified patients into four prognostic groups with significantly different OS (P < 0.001) as in the derivation cohort. In conclusion, multivariate analysis by Cox proportional hazards regression and serial landmark analyses clearly demonstrates that development of RBC-TD at any time during the course of MDS is associated with poor OS, independent of IPSS-R. This study demonstrates that dynamic assessment of RBC-TD provides additional prognostic value to IPSS-R and should be included in treatment decision algorithms for MDS patients.
Frequent Expression of MUC1, a Membrane-Associated Mucin, in Adult T-Cell Leukemia Cells.
Authors: Hiroo Hasegawa, Minori Komoda, Yasuaki Yamada, Suguru Yonezawa, Yasushi Miyazaki, Kunihiro Tsukasaki, Kazuhiro Nagai, Sunao Atogami, Akemi Osaka, Daisuke Sasaki, Kazuto Tsuruda, Shimeru Kamihira
Journal: Blood (2009)
CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial
Authors: Andrei R. Shustov, Yasuhiro Oki, Stefan Klaus Barta, Patrick B. Johnston, Pankaj Sharma, Tao Song, Sanjay Mourya
Journal: Blood (2016)
Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.
Authors: Klaus Podar, Giovanni Tonon, Marc S. Raab, Martin Sattler, Dean Abtahi, Yu-Tzu Tai, Steven LeGouill, Kenji Ishitsuka, Hiroshi Yasui, Ron A. Depinho, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood (2005)
High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.
Authors: Richard W Joseph, Krishna V. Komanduri, R. M Saliba, Amin Alousi, S. Giralt, Gabriela Rondon, Joyce Neumann, Cindy Trevino, Daniel R. Couriel, Richard Champlin, U. Popat
Journal: Blood (2008)
International criteria for electrocardiographic interpretation in athletes: Consensus statement
Authors: Jonathan A Drezner, Sanjay Sharma, Aaron Baggish, Michael Papadakis, Mathew G Wilson, Jordan M Prutkin, Andre La Gerche, Michael J Ackerman, Mats Borjesson, Jack C Salerno, Irfan M Asif, David S Owens, Eugene H Chung, Michael S Emery, Victor F Froelicher, Hein Heidbuchel, Carmen Adamuz, Chad A Asplund, Gordon Cohen, Kimberly G Harmon, Joseph C Marek, Silvana Molossi, Josef Niebauer, Hank F Pelto, Marco V Perez, Nathan R Riding, Tess Saarel, Christian M Schmied, David M Shipon, Ricardo Stein, Victoria L Vetter, Antonio Pelliccia, Domenico Corrado
Journal: British Journal of Sports Medicine (2017)

Sudden cardiac death (SCD) is the leading cause of mortality in athletes during sport. A variety of mostly hereditary, structural or electrical cardiac disorders are associated with SCD in young athletes, the majority of which can be identified or suggested by abnormalities on a resting 12-lead electrocardiogram (ECG). Whether used for diagnostic or screening purposes, physicians responsible for the cardiovascular care of athletes should be knowledgeable and competent in ECG interpretation in athletes. However, in most countries a shortage of physician expertise limits wider application of the ECG in the care of the athlete. A critical need exists for physician education in modern ECG interpretation that distinguishes normal physiological adaptations in athletes from distinctly abnormal findings suggestive of underlying pathology. Since the original 2010 European Society of Cardiology recommendations for ECG interpretation in athletes, ECG standards have evolved quickly, advanced by a growing body of scientific data and investigations that both examine proposed criteria sets and establish new evidence to guide refinements. On 26–27 February 2015, an international group of experts in sports cardiology, inherited cardiac disease, and sports medicine convened in Seattle, Washington (USA), to update contemporary standards for ECG interpretation in athletes. The objective of the meeting was to define and revise ECG interpretation standards based on new and emerging research and to develop a clear guide to the proper evaluation of ECG abnormalities in athletes. This statement represents an international consensus for ECG interpretation in athletes and provides expert opinion-based recommendations linking specific ECG abnormalities and the secondary evaluation for conditions associated with SCD.
Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer
Authors: S. X. Yang, J. P. Costantino, D. Nguyen, J. Jeong, E. P. Mamounas, N. Wolmark, C. Kim, K. Kidwell, S. Paik, S. M. Swain
Journal: Journal of Clinical Oncology (2009)

537 Background: We investigated the levels of tumor phospho-Akt(Ser473) (pAkt) and treatment outcome of patients with node-positive breast cancer after adjuvant treatment with doxorubicin/cyclophosphamide (AC) followed by four cycles of paclitaxel (PTX) (AC→PTX) compared with AC chemotherapy alone in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial. Methods: The primary tumors on B-28 tissue microarray were available from 1581 of 3060 patients enrolled. pAkt status was examined by immunohistochemistry with the antibody to pAkt(Ser473) (Cell Signaling Technology) at the National Cancer Institute. Levels of pAkt were quantitatively scored with the assistance of an Automated Digital Imaging System blinded to clinical outcome, and categorized by the staining index (intensity X % of staining /100) of &gt; 2 (high) and ≤ 2 (low). The association between tumor pAkt level and clinical outcome at 10 years was assessed using multivariate Cox modeling adjusting for age, tumor size, number of positive nodes, tumor grade, estrogen receptor and HER2 status. Results: Among patients with low tumor pAkt levels (n = 975), there was no DFS difference between those treated with or without PTX (adjusted HR = 1.02, p = 0.81). However, among patients with high tumor pAkt levels (n = 606), those treated with AC→PTX had a 26% reduction in DFS event rate compared to those treated with AC only (adjusted HR = 0.74, p = 0.02). There was no OS difference between treatment groups for those with low pAkt cancer (HR = 0.97, p = 0.80). In patients with high pAkt cancer, those treated with AC→PTX had a 20% reduction in death rate compared to those treated with AC only but this difference did not reach statistical significance (adjusted HR = 0.80, p = 0.17). Conclusions: High levels of Akt phosphorylation at Ser473 independently predict a DFS benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide in node-positive breast cancer. Patients with low levels of pAkt breast cancer may not benefit from the sequential addition of PTX to doxorubicin plus cyclophosphamide. [Table: see text]
Free Paper Session : Hepatitis C ; Diagnostic accuracy of extracellular matrix markers measured in the hepatic vein and peripheral vein in the prediction of advanced fibrosis (초)
Authors: Ki Tae Suk, Chang Hoon Kim, Seung Ha Park, Jae Youn Cheong, Sung Won Cho, Kwang Hyub Han, Jae Hoon Yoon, Yeon Soo Kim, Gwang Ho Baik, Jin Bong Kim, Dong Joon Kim
Journal: Clinical and Molecular Hepatology (2011)
MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma
Authors: Lipin Liu, Nan Bi, Lihong Wu, Xiao Ding, Yu Men, Wei Zhou, Lin Li, Weimin Zhang, Susheng Shi, Yongmei Song, Luhua Wang
Journal: Molecular Cancer (2017)

Lung adenocarcinoma (LAD) is considered to be a highly aggressive disease with heterogeneous prognosis and the molecular mechanisms underlying tumor progression remain elusive. Growing evidence demonstrates that the dysregulation of microRNAs (miRNAs) plays an important role in various tumor processes. The aim of this study is to discover prognostic miRNA and investigate its role involved in progression of LAD. Prognosis related miRNA was detected by miRNA microarray using formalin-fixed paraffin-embedded (FFPE) specimens from 87 patients with IIIA-N2 LAD. The cell proliferation was evaluated by Cell Titer 96 AQueous One Solution Cell Proliferation Assay (MTS), and the migration/invasion was evaluated by transwell assay. The bioinformatics methods and luciferase reporter assay were applied to detect the relationship between miRNA and its target. The mRNA and protein levels of miRNA target were determined by quantitative real time polymerase chain reaction (qRT-PCR) analysis, western blot and enzyme-linked immunosorbent assay (ELISA). Changes of angiogenesis induced by miRNA was evaluated by human umbilical vein endothelial cell (HUVEC) tube formation assay. Immunohistochemistry (IHC) analysis was performed in FFPE specimens of patients to evaluate the correlation between miR-29c with microvessel density (MVD) and vascular endothelial growth factor A (VEGFA) expression. MiR-29c expression downregulation was significantly associated with unfavorable prognosis in IIIA-N2 LAD. MiR-29c inhibited cell proliferation, migration and invasion in cell lines. Integrated analysis revealed that VEGFA was a direct target of miR-29c. MiR-29c reduced the capability of tumor cells to promote HUVEC tube formation. The compromised cell proliferation, migration/invasion and angiogenesis induced by miR-29c mimic transfection were reversed by transfection of VEGFA expression plasmid. Furthermore, the correlation of miR-29c with MVD and VEGFA was confirmed in patients' samples. MiR-29c acts as a tumor suppressor by targeting VEGFA and may represent a promising prognostic biomarker as well as a potential therapeutic target for LAD.
Website Characteristics and Physician Reviews on Commercial Physician-Rating Websites
Authors: Tara Lagu, Katherine Metayer, Michael Moran, Leidy Ortiz, Aruna Priya, Sarah L. Goff, Peter K. Lindenauer
Journal: JAMA (2017)

quantity of reviews that would accurately relay the experience of care with that physician.Given the demand by consumers for information about physicians, other methods for publishing patient feedback are being developed, 5 and some health systems are beginning to report quantitative reviews and narratives drawn from patient experience surveys. 6 Because of the scarcity of reviews on commercial sites, one of these other methods of publishing patient feedback may emerge as the dominant route by which patients seek reviews about physicians.Methods that use systematic data collection (eg, surveys) may have a greater chance of amassing a sufficient quantity and quality of reviews to allow patients to make inferences about patient experience of care.
Identification of Target Antigens Recognized in MGUS for Immunotherapeutic Approaches.
Authors: Simona Blotta, Roberto Bellucci, Pierfrancesco Tassone, Rao Prabhala, Paola Neri, Masood Shammas, Ramesh R. Batchu, Jooeun E. Bae, Cheng Li, Salvatore Venuta, Jerome Ritz, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2005)
Abstract P6-02-02: Uridine diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion
Authors: JM Arnold, U Rasaily, E Ramirez-Peña, R Pathak, R San Martin, P Purwaha, A Rao, N Putluri, D Rowley, A Sikora, S Mani, A Sreekumar
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
C-Terminal Defect of CD20 on T-Cell Leukemia/Lymphoma Cells: Implications for Resistance to Rituximab
Authors: Hiroyuki Takamatsu, Yoshihiro Yakushijin, Koji Miyazaki, Akiyoshi Takami, Masahide Yamazaki, Hirokazu Okumura, Shinji Nakao
Journal: Blood (2008)
Risk Factors for Outcomes of Family Haploidentical Allogeneic Stem Cell Transplantation for Adults with Acute Leukemias: A Survey on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Fabio Ciceri, Myriam Labopin, Vanderson Rocha, Jacob M. Rowe, Donald Bunjes, Paolo Di Bartolomeo, Francesco Frassoni, Massimo F. Martelli, Franco Aversa
Journal: Blood (2004)